Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Head and Neck Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Head and Neck Oncology” listed below:
1. “Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients”
by Kariem Sharaf, Axel Lechner, Stefan P. Haider, Robert Wiebringhaus, Christoph Walz, Gisela Kranz, Martin Canis, Frank Haubner, Olivier Gires and Philipp Baumeister
Curr. Oncol. 2021, 28(4), 2763–2774; https://doi.org/10.3390/curroncol28040241
Available online: https://www.mdpi.com/1718-7729/28/4/241
2. “Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report”
by Cristina Luongo, Tommaso Porcelli, Francesca Sessa, Maria Angela De Stefano, Francesco Scavuzzo, Vincenzo Damiano, Michele Klain, Claudio Bellevicine, Elide Matano, Giancarlo Troncone et al.
Curr. Oncol. 2021, 28(6), 5401–5407; https://doi.org/10.3390/curroncol28060450
Available online: https://www.mdpi.com/1718-7729/28/6/450
3. “Differential Expression of Non-Coding RNA Signatures in Thyroid Cancer between Two Ethnic Groups”
by Kristiana Rood, Khodeza Begum, Hanmin Wang, Yan C. Wangworawat, Ryan Davis, Celina R. Yamauchi, Mia C. Perez, Alfred A. Simental, Ria T. Laxa, Charles Wang et al.
Curr. Oncol. 2021, 28(5), 3610–3628; https://doi.org/10.3390/curroncol28050309
Available online: https://www.mdpi.com/1718-7729/28/5/309
4. “Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases”
by Christian Flörke, Aydin Gülses, Christina-Randi Altmann, Jörg Wiltfang, Henning Wieker and Hendrik Naujokat
Curr. Oncol. 2021, 28(3), 1886–1898; https://doi.org/10.3390/curroncol28030175
Available online: https://www.mdpi.com/1718-7729/28/3/175
5. “Use of Propensity Score Matching to Compare Short Outcomes from Transoral and External Surgical Approaches in Patients with Deep-Lobe Parotid Pleomorphic Adenomas”
by Yue Fan, Shuguang Li, Shuting Yu, Xiaoli Zhu, Xiaohua Shi, Wuyi Li, Zhiqiang Gao and Xingming Chen
Curr. Oncol. 2021, 28(4), 3115–3123; https://doi.org/10.3390/curroncol28040272
Available online: https://www.mdpi.com/1718-7729/28/4/272
6. “Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration”
by Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku et al.
Curr. Oncol. 2021, 28(4), 2409–2419; https://doi.org/10.3390/curroncol28040221
Available online: https://www.mdpi.com/1718-7729/28/4/221
7. “A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma”
by Zeynep Özözen Ayas and Gülgün Uncu
Curr. Oncol. 2021, 28(1), 560–564; https://doi.org/10.3390/curroncol28010055
Available online: https://www.mdpi.com/1718-7729/28/1/55
8. “Occurrence of Arrhythmias in Women with Thyroid Cancer Receiving Suppressive Doses of Levothyroxine”
by Karol Kaziród-Wolski, Aldona Kowalska, Janusz Sielski, Magdalena Biskup-Frużyńska and Grzegorz Piotrowski
Curr. Oncol. 2021, 28(6), 5009–5018; https://doi.org/10.3390/curroncol28060420
Available online: https://www.mdpi.com/1718-7729/28/6/420
9. “WNT8B as an Independent Prognostic Marker for Nasopharyngeal Carcinoma”
by Chawalit Ngernsombat, Pongphol Prattapong, Noppadol Larbcharoensub, Krittika Khotthong and Tavan Janvilisri
Curr. Oncol. 2021, 28(4), 2529–2539; https://doi.org/10.3390/curroncol28040230
Available online: https://www.mdpi.com/1718-7729/28/4/230
10. “Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options”
by Anouchka Modesto, Aurore Siegfried, Amelie Lusque, Sébastien Vergez, Jerome Sarini, Laurent Brouchet, Emmanuelle Uro-Coste, Pierre Graff-Cailleaud and Jean Pierre Delord
Curr. Oncol. 2021, 28(3), 1673–1680; https://doi.org/10.3390/curroncol28030156
Available online: https://www.mdpi.com/1718-7729/28/3/156
14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Psychosocial Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Psychosocial Oncology” listed below:
1. “COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients”
by Véronique Massicotte, Hans Ivers and Josée Savard
Curr. Oncol. 2021, 28(1), 294–300; https://doi.org/10.3390/curroncol28010034
Available online: https://www.mdpi.com/1718-7729/28/1/34
2. “Personality Traits and Urinary Symptoms Are Associated with Mental Health Distress in Patients with a Diagnosis of Prostate Cancer”
by Charles Gillis, Gabriela Ilie, Ross Mason, Gregory Bailly, Joseph Lawen, David Bowes, Nikhilesh Patil, Derek Wilke, Robert David Harold Rutledge, David Bell et al.
Curr. Oncol. 2021, 28(4), 2993–3002; https://doi.org/10.3390/curroncol28040262
Available online: https://www.mdpi.com/1718-7729/28/4/262
3. “Examining the Pathoplastic Moderating Role of Education on the Association between Depressive Mood and Self-Rated Health among Cancer Survivors: A Population-Based Study”
by Anao Zhang, Kaipeng Wang and Adam S. DuVall
Curr. Oncol. 2021, 28(5), 4042–4052; https://doi.org/10.3390/curroncol28050343
Available online: https://www.mdpi.com/1718-7729/28/5/343
4. “Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic”
by David Forner, Sarah Murnaghan, Geoffrey Porter, Ross J. Mason, Paul Hong, S. Mark Taylor, James Bentley, Gregory Hirsch, Christopher W. Noel, Matthew H. Rigby et al.
Curr. Oncol. 2021, 28(3), 1867–1878; https://doi.org/10.3390/curroncol28030173
Available online: https://www.mdpi.com/1718-7729/28/3/173
5. “Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors”
by Cassidy Bradley, Gabriela Ilie, Cody MacDonald, Lia Massoeurs, Jasmine Dang Cam-Tu Vo and Robert David Harold Rutledge
Curr. Oncol. 2021, 28(5), 3900–3917; https://doi.org/10.3390/curroncol28050333
Available online: https://www.mdpi.com/1718-7729/28/5/333
6. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278
13 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Medical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Medical Oncology” listed below:
1. “Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome”
by Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns and Hendrik Everaert
Curr. Oncol. 2021, 28(3), 1630–1640; https://doi.org/10.3390/curroncol28030152
Available online: https://www.mdpi.com/1718-7729/28/3/152
2. “The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design”
by Deanna Saunders, Michelle Liu, Lisa Vandermeer, Mashari Jemaan Alzahrani, Brian Hutton and Mark Clemons
Curr. Oncol. 2021, 28(5), 3959–3977; https://doi.org/10.3390/curroncol28050337
Available online: https://www.mdpi.com/1718-7729/28/5/337
3. “Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario”
by Dalia Kamel, Veronica Youssef, Wilma M. Hopman and Mihaela Mates
Curr. Oncol. 2021, 28(3), 2190–2198; https://doi.org/10.3390/curroncol28030203
Available online: https://www.mdpi.com/1718-7729/28/3/203
4. “Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice”
by Joyce O’Shaughnessy, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn and Andreas Schneeweiss
Curr. Oncol. 2021, 28(4), 2741–2752; https://doi.org/10.3390/curroncol28040239
Available online: https://www.mdpi.com/1718-7729/28/4/239
5. “18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center”
by Ur Metser, Claudia Ortega, Douglas Hussey, Rosanna Chan, Alejandro Berlin, Antonio Finelli and Patrick Veit-Haibach
Curr. Oncol. 2021, 28(5), 3251–3258; https://doi.org/10.3390/curroncol28050282
Available online: https://www.mdpi.com/1718-7729/28/5/282
6. “The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group”
by Kelvin K. W. Chan, Matthew C. Cheung, Dean A. Regier, Annette Hay, Alexander V. Louie, Winson Y. Cheung, Jean-Eric Tarride, Suji Udayakumar and Nicole Mittmann
Curr. Oncol. 2021, 28(5), 3649–3658; https://doi.org/10.3390/curroncol28050311
Available online: https://www.mdpi.com/1718-7729/28/5/311
7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36
8. “Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group”
by Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones et al.
Curr. Oncol. 2021, 28(5), 4174–4183; https://doi.org/10.3390/curroncol28050354
Available online: https://www.mdpi.com/1718-7729/28/5/354
9. “Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise”
by Wei Fang Dai, Erica Craig, Brent Fraser, Alex Chambers, Helen Mai, M. Bryson Brown, Craig C. Earle, William K. Evans, Marc Geirnaert, Marianne Taylor et al.
Curr. Oncol. 2021, 28(6), 4645–4654; https://doi.org/10.3390/curroncol28060392
Available online: https://www.mdpi.com/1718-7729/28/6/392
10. “Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec”
by Jason S. Agulnik, Goulnar Kasymjanova, Carmela Pepe, Manjusha Hurry, Ryan N. Walton, Lama Sakr, Victor Cohen and David Small
Curr. Oncol. 2021, 28(6), 5179–5191; https://doi.org/10.3390/curroncol28060434
Available online: https://www.mdpi.com/1718-7729/28/6/434
12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Neuro-Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Neuro-Oncology” listed below:
1. “Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation”
by Astrid Ellen Grams, Stephanie Mangesius, Ruth Steiger, Ivan Radovic, Andreas Rietzler, Lisa Maria Walchhofer, Malik Galijašević, Julian Mangesius, Martha Nowosielski, Christian Franz Freyschlag et al.
Curr. Oncol. 2021, 28(6), 5041–5053; https://doi.org/10.3390/curroncol28060424
Available online: https://www.mdpi.com/1718-7729/28/6/424
2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226
3. “Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients”
by Archya Dasgupta, Jayson Co, Jeff Winter, Barbara-Ann Millar, Normand Laperriere, Derek S. Tsang, Monique van Prooijen, Andrei Damyanovich, Robert Heaton, Catherine Coolens et al.
Curr. Oncol. 2021, 28(1), 549–559; https://doi.org/10.3390/curroncol28010054
Available online: https://www.mdpi.com/1718-7729/28/1/54
4. “The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study”
by Ondrej Kalita, Zuzana Sporikova, Marian Hajduch, Magdalena Megova Houdova, Rastislav Slavkovsky, Lumir Hrabalek, Matej Halaj, Yvona Klementova, Martin Dolezel, Jiri Drabek et al.
Curr. Oncol. 2021, 28(2), 1280–1293; https://doi.org/10.3390/curroncol28020122
Available online: https://www.mdpi.com/1718-7729/28/2/122
5. “A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases”
by William J. Phillips, Tabassom Baghai, Michael Ong, Bryan Lo, Andrea M. Ibrahim, Tyler K.T. Smith and Xinni Song
Curr. Oncol. 2021, 28(1), 428–439; https://doi.org/10.3390/curroncol28010045
Available online: https://www.mdpi.com/1718-7729/28/1/45
6. “Feasibility on the Use of Radiomics Features of 11[C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model”
by Giorgio Russo, Alessandro Stefano, Pierpaolo Alongi, Albert Comelli, Barbara Catalfamo, Cristina Mantarro, Costanza Longo, Roberto Altieri, Francesco Certo, Sebastiano Cosentino et al.
Curr. Oncol. 2021, 28(6), 5318–5331; https://doi.org/10.3390/curroncol28060444
Available online: https://www.mdpi.com/1718-7729/28/6/444
7. “Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma”
by Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi et al.
Curr. Oncol. 2021, 28(1), 726–739; https://doi.org/10.3390/curroncol28010071
Available online: https://www.mdpi.com/1718-7729/28/1/71
8. “Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy”
by Eric K. Nguyen, Gregory R. Pond, Jeffrey N. Greenspoon, Anthony C. Whitton and Crystal Hann
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314
9. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314
10. “Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience”
by Maria Camila Quinones, Karl Bélanger, Émilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, Laura G. Masucci, David Roberge, Cynthia Menard, Carole Lambert, France Berthelet et al.
Curr. Oncol. 2021, 28(4), 3104–3114; https://doi.org/10.3390/curroncol28040271
Available online: https://www.mdpi.com/1718-7729/28/4/271
12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Hematology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Hematology” listed below:
1. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431
2. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89
3. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390
4. “Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor”
by Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote and Amitkumar Mehta
Curr. Oncol. 2021, 28(1), 837–841; https://doi.org/10.3390/curroncol28010081
Available online: https://www.mdpi.com/1718-7729/28/1/81
5. “Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada”
by Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, Philippe Thebault, Andrew Aw, Versha Banerji, Isabelle Fleury and Carolyn Owen
Curr. Oncol. 2021, 28(1), 332–345; https://doi.org/10.3390/curroncol28010037
Available online: https://www.mdpi.com/1718-7729/28/1/37
6. “Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB)”
by Melanie Barz, Kaywan Aftahy, Insa Janssen, Yu-Mi Ryang, Georg Prokop, Stephanie E. Combs, Philipp J. Jost, Bernhard Meyer and Jens Gempt
Curr. Oncol. 2021, 28(5), 3891–3899; https://doi.org/10.3390/curroncol28050332
Available online: https://www.mdpi.com/1718-7729/28/5/332
7. “The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry”
by Chris Varghese, Tracey Immanuel, Anna Ruskova, Edward Theakston and Maggie L. Kalev-Zylinska
Curr. Oncol. 2021, 28(2), 1544–1557; https://doi.org/10.3390/curroncol28020146
Available online: https://www.mdpi.com/1718-7729/28/2/146
8. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407
9 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Bone and Soft Tissue Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Bone and Soft Tissue Oncology” shown below:
1. “A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases”
by Taylor Kandler, Eliane Cortez, Lani Clinton, Amanda Hemmerich, Osama Ahmed, Ralph Wong, Taylor Forns, Andrea J. MacNeill, Trevor D. Hamilton, Mohammadali Khorasani et al.
Curr. Oncol. 2022, 29(2), 1279–1297; https://doi.org/10.3390/curroncol29020109
Available online: https://www.mdpi.com/1718-7729/29/2/109
2. “Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw”
by Veronica Mollica, Giacomo Nuvola, Elisa Tassinari, Maria Concetta Nigro, Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Costantino Errani and Francesco Massari
Curr. Oncol. 2022, 29(3), 1709–1722; https://doi.org/10.3390/curroncol29030142
Available online: https://www.mdpi.com/1718-7729/29/3/142
3. “Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155–4177; https://doi.org/10.3390/curroncol29060332
Available online: https://www.mdpi.com/1718-7729/29/6/332
4. “Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor”
by Saya Tamura, Takuma Hayashi, Tomoyuki Ichimura, Nobuo Yaegashi, Kaoru Abiko and Ikuo Konishi
Curr. Oncol. 2022, 29(4), 2350–2363; https://doi.org/10.3390/curroncol29040190
Available online: https://www.mdpi.com/1718-7729/29/4/190
5. “Outcomes of Hip Reconstruction for Metastatic Acetabular Lesions: A Scoping Review of the Literature”
by Sandeep Krishan Nayar, Thomas A. Kostakos, Olga Savvidou, Konstantinos Vlasis and Panayiotis J. Papagelopoulos
Curr. Oncol. 2022, 29(6), 3849–3859; https://doi.org/10.3390/curroncol29060307
Available online: https://www.mdpi.com/1718-7729/29/6/307
6. “Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis”
by Joachim Thorkildsen, Thale Asp Strøm, Nils Jørgen Strøm, Simen Sellevold and Ole-Jacob Norum
Curr. Oncol. 2022, 29(5), 3460–3471; https://doi.org/10.3390/curroncol29050279
Available online: https://www.mdpi.com/1718-7729/29/5/279
7. “Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients”
by Michael Knitschke, Sophia Sonnabend, Fritz Christian Roller, Jörn Pons-Kühnemann, Daniel Schmermund, Sameh Attia, Philipp Streckbein, Hans-Peter Howaldt and Sebastian Böttger
Curr. Oncol. 2022, 29(5), 3375–3392; https://doi.org/10.3390/curroncol29050274
Available online: https://www.mdpi.com/1718-7729/29/5/274
8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Health Economics”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Health Economics” shown below:
1. “The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context”
by Ivan Yanev, Jessy Gatete, Jr., Armen G. Aprikian, Jason Robert Guertin and Alice Dragomir
Curr. Oncol. 2022, 29(5), 3393–3424; https://doi.org/10.3390/curroncol29050275
Available online: https://www.mdpi.com/1718-7729/29/5/275
2. “The Pathway for New Cancer Drug Access in Canada”
by Joanna Gotfrit, William Dempster, Johanne Chambers and Paul Wheatley-Price
Curr. Oncol. 2022, 29(2), 455–464; https://doi.org/10.3390/curroncol29020041
Available online: https://www.mdpi.com/1718-7729/29/2/41
3. “Determinants of the Cancer Drug Funding Process in Canada”
by Joanna Gotfrit, Ashley Jackson, John J. W. Shin, David J. Stewart, Ranjeeta Mallick and Paul Wheatley-Price
Curr. Oncol. 2022, 29(3), 1997–2007; https://doi.org/10.3390/curroncol29030162
Available online: https://www.mdpi.com/1718-7729/29/3/162
4. “Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations”
by Louise Binder, Majd Ghadban, Christina Sit and Kathleen Barnard
Curr. Oncol. 2022, 29(3), 1514–1526; https://doi.org/10.3390/curroncol29030127
Available online: https://www.mdpi.com/1718-7729/29/3/127
5. “Challenges and Adaptations for Providing Smoking Cessation for Patients with Cancer across Canada during the COVID-19 Pandemic”
by Graham W. Warren, Caroline Silverman and Michelle Halligan
Curr. Oncol. 2022, 29(4), 2263–2271; https://doi.org/10.3390/curroncol29040184
Available online: https://www.mdpi.com/1718-7729/29/4/184
6. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18
7. “Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status”
by Marie-France Savard, Elizabeth N. Kornaga, Adriana Matutino Kahn and Sasha Lupichuk
Curr. Oncol. 2022, 29(1), 383–391; https://doi.org/10.3390/curroncol29010034
Available online: https://www.mdpi.com/1718-7729/29/1/34
8. “Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada”
by Andrea M. Guggenbickler, Heather K. Barr, Jeffrey S. Hoch and Carolyn S. Dewa
Curr. Oncol. 2022, 29(10), 7285–7304; https://doi.org/10.3390/curroncol29100574
Available online: https://www.mdpi.com/1718-7729/29/10/574
9. “Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021”
by Catherine Lau and George Dranitsaris
Curr. Oncol. 2022, 29(11), 8031–8042; https://doi.org/10.3390/curroncol29110635
Available online: https://www.mdpi.com/1718-7729/29/11/635
10. “Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group”
by Wei Fang Dai, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden et al.
Curr. Oncol. 2022, 29(3), 2046–2063; https://doi.org/10.3390/curroncol29030165
Available online: https://www.mdpi.com/1718-7729/29/3/165
8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Childhood, Adolescent and Young Adult Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” shown below:
1. “Subsequent Malignant Neoplasm of Bone in Children and Adolescent—Possibility of Multimodal Treatment”
by Anna Raciborska, Katarzyna Bilska, Tomasz Koziński and Carlos Rodriguez-Galindo
Curr. Oncol. 2022, 29(2), 1001–1007; https://doi.org/10.3390/curroncol29020085
Available online: https://www.mdpi.com/1718-7729/29/2/85
2. “The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review”
by Stephanie J. Kendall, Jodi E. Langley, Mohsen Aghdam, Bruce N. Crooks, Nicholas Giacomantonio, Stefan Heinze-Milne, Will J. Johnston, Melanie R. Keats, Sharon L. Mulvagh and Scott A. Grandy
Curr. Oncol. 2022, 29(9), 6350–6363; https://doi.org/10.3390/curroncol29090500
Available online: https://www.mdpi.com/1718-7729/29/9/500
3. “Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study”
by Carla Vlooswijk, Lonneke V. van de Poll-Franse, Silvie H. M. Janssen, Esther Derksen, Milou J. P. Reuvers, Rhodé Bijlsma, Suzanne E. J. Kaal, Jan Martijn Kerst, Jacqueline M. Tromp, Monique E. M. M. Bos et al.
Curr. Oncol. 2022, 29(8), 5407–5425; https://doi.org/10.3390/curroncol29080428
Available online: https://www.mdpi.com/1718-7729/29/8/428
4. “The Transformation of Adolescent and Young Adult Oncological and Supportive Care in Canada: A Mixed Methods Study”
by Jonathan Avery, Emily Wong, Christine Harris, Stacy Chapman, Serena Uppal, Shaayini Shanawaz, Annemarie Edwards, Laura Burnett, Tushar Vora and Abha A. Gupta
Curr. Oncol. 2022, 29(7), 5126–5138; https://doi.org/10.3390/curroncol29070406
Available online: https://www.mdpi.com/1718-7729/29/7/406
5. “Reflections of Moral Suffering, Resilience, and Wisdom of Pediatric Oncology Social Workers during the COVID-19 Pandemic”
by Barbara Jones, Nancy Cincotta, Wendy Pelletier, Abigail Fry and Lori Wiener
Curr. Oncol. 2022, 29(9), 6177–6185; https://doi.org/10.3390/curroncol29090485
Available online: https://www.mdpi.com/1718-7729/29/9/485
7 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Dermato-Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Dermato-Oncology” shown below:
1. “Cutaneous Melanoma in Alpine Population: Incidence Trends and Clinicopathological Profile”
by Alessandra Buja, Massimo Rugge, Giuseppe De Luca, Emanuela Bovo, Manuel Zorzi, Chiara De Toni, Claudia Cozzolino, Antonella Vecchiato, Paolo Del Fiore, Romina Spina et al.
Curr. Oncol. 2022, 29(3), 2165–2173; https://doi.org/10.3390/curroncol29030175
Available online: https://www.mdpi.com/1718-7729/29/3/175
2. “Assessing Choroidal Nevi, Melanomas and Indeterminate Melanocytic Lesions Using Multimodal Imaging—A Retrospective Chart Review”
by Fredy Geiger, Sadiq Said, Anahita Bajka, Mario Damiano Toro, Maximilian Robert Justus Wiest, Marc Stahel, Daniel Barthelmes and Sandrine Anne Zweifel
Curr. Oncol. 2022, 29(2), 1018–1028; https://doi.org/10.3390/curroncol29020087
Available online: https://www.mdpi.com/1718-7729/29/2/87
3. “Treatment of Basal Cell Carcinoma with Electrochemotherapy: Insights from the InspECT Registry (2008–2019)”
by Giulia Bertino, Tobian Muir, Joy Odili, Ales Groselj, Roberto Marconato, Pietro Curatolo, Erika Kis, Camilla Kjaer Lonkvist, James Clover, Pietro Quaglino et al.
Curr. Oncol. 2022, 29(8), 5324–5337; https://doi.org/10.3390/curroncol29080423
Available online: https://www.mdpi.com/1718-7729/29/8/423
4. “Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes”
by Thilo Gambichler, Yi-Pei Lee, Ilske Oschlies, Christina H. Scheel, Wolfram Klapper, Nico Nowack, Martin Doerler, Markus Stücker, Nasreddin Abolmaali and Laura Susok
Curr. Oncol. 2022, 29(4), 2395–2405; https://doi.org/10.3390/curroncol29040194
Available online: https://www.mdpi.com/1718-7729/29/4/194
5. “Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic”
by Marta Pabianek, Aleksandra Lesiak, Dariusz Nejc, Łukasz Kuncman, Joanna Narbutt, Małgorzata Skibińska and Magdalena Ciążyńska
Curr. Oncol. 2022, 29(10), 7794–7801; https://doi.org/10.3390/curroncol29100616
Available online: https://www.mdpi.com/1718-7729/29/10/616
6. “An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers”
by Clio Dessinioti and Alexander J. Stratigos
Curr. Oncol. 2022, 29(11), 8886–8903; https://doi.org/10.3390/curroncol29110699
Available online: https://www.mdpi.com/1718-7729/29/11/699
7. “Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis”
by Lise Mayrin Økland Thunestvedt, Lars Helgeland, Ingeborg Margrethe Bachmann, Åsa Karlsdottir, Torjan Magne Haslerud and Håkon Reikvam
Curr. Oncol. 2022, 29(4), 2193–2198; https://doi.org/10.3390/curroncol29040178
Available online: https://www.mdpi.com/1718-7729/29/4/178
8. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237
2 October 2023
MDPI Insights: The CEO's Letter #4 - MDPI Presence in China
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

Open Access in China
It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.
Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!
Open Access Policy in China
As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.
Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.
In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.
In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.

Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.
In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
Our Strength is in Our People
With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.
In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.
Impactful Research

MDPI Awards
To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.
In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.
Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.
To learn more about MDPI Awards and to find out which are currently available, please click here.
MDPI Awards to Scholars from China
Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.
MDPI’s Tu Youyou Award

Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.
The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.
2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu
Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.
Highly Cited Articles by Chinese Scholars Published in MDPI
Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.
Read more:
- Tu Youyou Award
- World Sustainability Awards
- Available Awards
Inside MDPI
Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.
Marketing Department in China
During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.
I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.
Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.
Coming Together for Science

Collaborations, Scholarships and Meetings
MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.
Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.
Scholarships in China
Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).
Meeting with the Society of Chinese University Journals (CUJS)

Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.
I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.
We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.
MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.
Meeting with National Science Library, Chinese Academy of Sciences (NSLC)

Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.
We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.
In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.
The Numbers
As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.
At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.
Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.
Closing Thoughts
Final Reflections on our MDPI Offices in Beijing and Wuhan

Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.
I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.
Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.
95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).
91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.
Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.
Hospitality and Service
Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.
I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.
Chief Executive Officer
MDPI AG